REGN|Analyst Targets
REGN|Company Info
REGN|Insider Trading
REGN|Fundamentals
REGN|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $16.07 | - | - |
| Q2'26 | $13.21 | $14.29 | +8.2% |
| Q1'26 | $8.90 | $9.47 | +6.4% |
| Q4'25 | $10.84 | $11.44 | +5.5% |
| Q3'25 | $9.64 | $11.83 | +22.7% |
| Q2'25 | $8.44 | $12.89 | +52.7% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $4.6B | - | - |
| Q2'26 | $3.9B | $4.3B | +10.3% |
| Q1'26 | $3.5B | $3.6B | +3.5% |
| Q4'25 | $3.9B | $3.9B | +0.4% |
| Q3'25 | - | $3.8B | - |
| Q2'25 | - | $3.7B | - |
REGN|Monthly Returns
Market Data
REGN Stock Snapshot
- Market cap
- 77.34B
- P/E ratio
- 17.9
- Day range
- $755.21 – $770.20
- News sentiment
- 80/100 · Bullish
- Analyst target
- $859.69 (+12.1%)
- Consensus
- Buy · 40 analysts
Momentum has flattened on REGN, leaving the next move dependent on news rather than the chart. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.
Reverse DCF
What growth is priced into REGN?
At today's price, Regeneron Pharmaceuticals, Inc. needs to grow free cash flow about 3.3% a year for the next 10 years to justify its valuation at a 8.81% cost of capital. Over its actual history it has compounded free cash flow at 24.6% a year, so the market is asking for 21.3 percentage points below its own delivered rate. On that basis REGN looks priced below what its own growth record supports.
- Implied FCF growth
- 3.3%
- Historical FCF CAGR
- 24.6%
- Growth gap
- -21.3 pts
- Verdict
- CHEAP
- Discount rate (WACC)
- 8.81%
- Beta
- 0.75
Behaviour On Record
What REGN's own history says about today's numbers
- Realized volatility (21d)
- 26.0% 35th pct
- Below its peak
- -37.3%
- vs 200-day average
- +2.4%
- Up days (1y)
- 49%
Regeneron Pharmaceuticals, Inc. is currently running 26.0% annualised volatility over the last 21 sessions. Measured against REGN's own 13 years of daily returns rather than a market-wide average, that is the 35th percentile — on the quiet side for this stock, against a typical reading of 28.7%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
REGN is trading -37.3% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -27.5%, and the deepest was -41.5% in 2024. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits +2.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 43rd percentile — close to the gap it normally carries. Over the past year REGN closed higher on 49% of sessions, and it is currently 1 session into a falling streak.
On October specifically: over 13 years of records, REGN finished the month higher 6 of 13 times, with a median return of -1.0% and an average of -0.3%. Its strongest month historically has been July at +5.3% on average, its weakest April at -4.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: REGN has opened more than 2% away from the prior close in 112 of 3,267 sessions (3.4% of the time), with the largest gaps running +24.3% and -12.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, REGN moved an average of 3.5% in the session after earnings, closing higher 3 of those 3 times, with a median move of +3.8% and a largest of +4.1%.
All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against REGN's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of REGN's sector?
Regeneron Pharmaceuticals, Inc. sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Biotechnology industry group, REGN ranks 7th of 15 tracked industries, improving.
- Sector rank
- #3 of 12
- Sector state
- Leading
- Sector rotation score
- 91
- Industry rank
- #7 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on REGN?
RBC Capital most recently reiterated its rating on Regeneron Pharmaceuticals, Inc. to Sector Perform on Oct 8, 2026 with a price target of $810 (from $737). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.
- Latest action
- RBC Capital — Sector Perform
- 90-day upgrades
- 1
- 90-day downgrades
- 0
- Net rating momentum
- +1
Peers & ETF holders
REGN peers & ETF holders
BiotechnologyMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▲ Buy | 9,075,153 | 9.00% | $7.00B | 2026-01-29 |
| BlackRock, Inc. | ▲ Buy | 9,113,506 | 9.04% | $5.68B | 2026-08-07 |
| Invesco Ltd. | ▲ Buy | 3,940,665 | 3.91% | $2.46B | 2026-08-14 |
| JPMorgan Chase & Co | ▼ Sell | 3,774,199 | 3.74% | $2.38B | 2026-08-12 |
| Geode Capital Management, LLC | ▲ Buy | 2,625,810 | 2.60% | $1.63B | 2026-08-12 |
| Loomis Sayles & Co L P | ▼ Sell | 1,859,172 | 1.84% | $1.16B | 2026-08-14 |
| Morgan Stanley | ▲ Buy | 1,397,712 | 1.39% | $871.53M | 2026-08-13 |
| Bank of America Corp | ▲ Buy | 1,291,053 | 1.28% | $805.02M | 2026-08-14 |
| Wellington Management Group LLP | ▼ Sell | 1,270,087 | 1.26% | $791.95M | 2026-08-14 |
| Norges Bank | ▼ Sell | 1,172,808 | 1.16% | $731.29M | 2026-08-12 |
| Goldman Sachs Group Inc | ▼ Sell | 1,163,191 | 1.15% | $725.30M | 2026-08-14 |
| AQR Capital Management LLC | ▼ Sell | 1,126,080 | 1.12% | $702.16M | 2026-08-14 |
| Northern Trust Corp | ▼ Sell | 916,467 | 0.91% | $571.45M | 2026-08-13 |
| FMR LLC (Fidelity) | ▼ Sell | 831,964 | 0.83% | $518.76M | 2026-08-13 |
| Capital World Investors | ▼ Sell | 814,925 | 0.81% | $508.14M | 2026-08-12 |
| Two Sigma Investments, LP | ▼ Sell | 656,124 | 0.65% | $409.12M | 2026-08-14 |
| Man Group plc | ▲ Buy | 436,956 | 0.43% | $272.46M | 2026-08-14 |
| Neuberger Berman Group LLC | ▼ Sell | 421,976 | 0.42% | $263.12M | 2026-08-13 |
| AllianceBernstein L.P. | ▼ Sell | 292,338 | 0.29% | $225.87M | 2026-08-14 |
| Citigroup Inc | ▲ Buy | 346,637 | 0.34% | $216.14M | 2026-08-03 |
| Janus Henderson Group plc | ▲ Buy | 209,248 | 0.21% | $161.64M | 2026-05-18 |
| Squarepoint Ops LLC | ▲ Buy | 198,567 | 0.20% | $123.81M | 2026-08-14 |
| Susquehanna International Group, LLP | ▲ Buy | 180,219 | 0.18% | $112.37M | 2026-08-14 |
| Millennium Management LLC | ▲ Buy | 165,120 | 0.16% | $102.96M | 2026-08-14 |
| Renaissance Technologies LLC | ▲ Buy | 148,222 | 0.15% | $92.42M | 2026-08-13 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2026-05-15 | 2026-06-08 |
| Alan Armstrong | Senate | OK | ▲ Buy | $1K - $15K | 2026-03-27 | 2026-07-21 |
| Julia Letlow | House | LA05 | ▲ Buy | $1K - $15K | 2026-02-12 | 2026-03-12 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2025-11-18 | 2025-12-15 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $1K - $15K | 2025-05-15 | 2025-06-09 |
| Byron Donalds | House | FL19 | ▼ Sell | $1K - $15K | 2025-04-10 | 2025-05-24 |
| Rob Bresnahan | House | PA08 | ▼ Sell | $1K - $15K | 2025-04-08 | 2025-05-08 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $15K - $50K | 2025-04-07 | 2025-05-08 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-04-01 | 2025-05-14 |
| Rob Bresnahan | House | PA08 | ▼ Sell | $1K - $15K | 2025-02-25 | 2025-03-27 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-02-12 | 2025-03-12 |
| Josh Gottheimer | House | NJ05 | ▼ Sell | $1K - $15K | 2025-01-24 | 2025-02-10 |
| Julie Johnson | House | TX32 | ▲ Buy | $1K - $15K | 2025-01-15 | 2025-02-12 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2024-04-04 | 2024-05-15 |
| Tommy Tuberville | Senate | AL | ▲ Buy | $1K - $15K | 2023-04-03 | 2023-05-12 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2022-03-30 | 2022-04-08 |
| Tommy Tuberville | Senate | AL | ▲ Buy | $1K - $15K | 2021-03-29 | 2021-07-23 |
| Sheldon Whitehouse | Senate | RI | ▼ Sell | $15K - $50K | 2017-12-18 | 2018-01-10 |
| Sheldon Whitehouse | Senate | RI | ▲ Buy | $1K - $15K | 2017-05-16 | 2017-06-08 |
| Sheldon Whitehouse | Senate | RI | ▲ Buy | $1K - $15K | 2016-09-06 | 2016-10-07 |
| Sheldon Whitehouse | Senate | RI | ▲ Buy | $1K - $15K | 2016-05-24 | 2016-06-16 |
| Susan M. Collins | Senate | ME | ▼ Sell | $1K - $15K | 2014-01-30 | 2014-02-05 |